{"transactions":[{"id":1225981,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":82410,"kind":"organization","name":"Cystic Fibrosis Foundation","position":1,"cik":"0001957515","reported_name":"Cystic Fibrosis Foundation","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series X Preferred Stock","published_at":"2025-03-04T21:31:04.000Z","date":"2024-07-15","kind":"exercise","planned":false,"acquired":false,"shares":8547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the Certificate of Designation of Preferences, Rights and Limitations (the \"Certificate of Designation\") governing the Series X Non-Voting Convertible Preferred Stock (\"Series X Preferred Stock\"), on July 15, 2024 (the \"Stockholder Approval Date\"), 8,547 shares of Series X Preferred Stock held by the Reporting Person automatically converted into 8,547,000 shares of Common Stock; following the Reverse Split, such shares were combined to 854,700 shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of the third business day after the Stockholder Approval Date, each share of Series X Preferred Stock became convertible at any time at the election of the holder into 100 shares of Common Stock (as adjusted pursuant to the Reverse Split, and subject to further adjustment), subject to a beneficial ownership limitation, in accordance with the Certificate of Designation. The Series X Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"As of the third business day after the Stockholder Approval Date, each share of Series X Preferred Stock became convertible at any time at the election of the holder into 100 shares of Common Stock (as adjusted pursuant to the Reverse Split, and subject to further adjustment), subject to a beneficial ownership limitation, in accordance with the Certificate of Designation. The Series X Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a ten-for-one reverse stock split of the Issuer's common stock that was effected on August 26, 2024 (the \"Reverse Split\")."}],"balance_after":13088,"derivative":{"underlying":"Common Stock","underlying_shares":854700},"source":{"system":"sec-edgar","filing":"0000950170-25-032174","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1739174/000095017025032174/ownership.xml","form_type":"5"}},{"id":1225980,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":82410,"kind":"organization","name":"Cystic Fibrosis Foundation","position":1,"cik":"0001957515","reported_name":"Cystic Fibrosis Foundation","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2025-03-04T21:31:04.000Z","date":"2024-07-15","kind":"exercise","planned":false,"acquired":true,"shares":854700,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a ten-for-one reverse stock split of the Issuer's common stock that was effected on August 26, 2024 (the \"Reverse Split\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the Certificate of Designation of Preferences, Rights and Limitations (the \"Certificate of Designation\") governing the Series X Non-Voting Convertible Preferred Stock (\"Series X Preferred Stock\"), on July 15, 2024 (the \"Stockholder Approval Date\"), 8,547 shares of Series X Preferred Stock held by the Reporting Person automatically converted into 8,547,000 shares of Common Stock; following the Reverse Split, such shares were combined to 854,700 shares of Common Stock."}],"balance_after":1787758,"source":{"system":"sec-edgar","filing":"0000950170-25-032174","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739174/000095017025032174/ownership.xml","form_type":"5"}},{"id":1510358,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":82410,"kind":"organization","name":"Cystic Fibrosis Foundation","position":1,"cik":"0001957515","reported_name":"Cystic Fibrosis Foundation","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to purchase common stock","published_at":"2024-05-17T20:05:17.000Z","date":"2024-05-15","kind":"other","planned":false,"acquired":false,"shares":4778265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The warrant was exercisable beginning on February 27, 2023, for that number of shares that would not result in the Reporting Person beneficially owning more than 9.99% of the number of shares of common stock then issued and outstanding upon such exercise, and became exercisable in full on May 15, 2024. The warrant does not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The warrant was exercisable beginning on February 27, 2023, for that number of shares that would not result in the Reporting Person beneficially owning more than 9.99% of the number of shares of common stock then issued and outstanding upon such exercise, and became exercisable in full on May 15, 2024. The warrant does not expire."}],"balance_after":0,"derivative":{"exercise_price":0.001,"underlying":"Common stock","underlying_shares":4778265},"source":{"system":"sec-edgar","filing":"0000950170-24-061622","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1739174/000095017024061622/ownership.xml","form_type":"4"}},{"id":1510357,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":82410,"kind":"organization","name":"Cystic Fibrosis Foundation","position":1,"cik":"0001957515","reported_name":"Cystic Fibrosis Foundation","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2024-05-17T20:05:17.000Z","date":"2024-05-15","kind":"other","planned":false,"acquired":true,"shares":4778265,"price":0.001,"value":4778.265,"ownership":{"direct":true},"balance_after":9330580,"source":{"system":"sec-edgar","filing":"0000950170-24-061622","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739174/000095017024061622/ownership.xml","form_type":"4"}}]}